亚胺培南/西司他丁治疗血流感染的蒙特卡洛模拟方案与其临床疗效的相关性研究  

Study on the correlation between monte carlo simulation program of imipenem/cilastatin and its clinical efficacy in treating blood stream infections with Escherichia coli

作　　者：展冠军[1] 朱国龙[1] 戴真南[1] 陆瑾[1] Zhan Guan-jun;Zhu Guo-long;Dai Zhen-nan;Lu Jin(Department of Pharmacy,Zhongda Hospital Affiliated to Southeast University,Nanjing 210009)

机构地区：[1]东南大学附属中大医院药学部,南京210009

出　　处：《中国抗生素杂志》2018年第12期1565-1568,共4页Chinese Journal of Antibiotics

基　　金：江苏省药学会基金项目(No.A2017044)

摘　　要：目的根据药动学/药效学(PK/PD)理论,采用蒙特卡洛模拟亚胺培南/西司他丁对大肠埃希菌所致的血流感染给药方案,同时结合亚胺培南/西司他丁对血流感染的临床疗效,对两者进行相关性研究。方法回顾性调查我院2013年7月—2016年6月引起血流感染的大肠埃希菌对亚胺培南/西司他丁的耐药监测报告,选择亚胺培南/西司他丁给药方案(0.5g q8h、0.5g q6h、1.0g q12h和1.0g q8h),分别计算出蒙特卡洛模拟10000例"真实患者"的累积反应分数(CFR)和临床疗效指数(CEI),用SPSS24.0版软件对CFR与CEI进行相关性分析。结果亚胺培南/西司他丁给药方案中0.5g q6h的CFR为85.30%;各给药方案的CEI均大于80%。结论蒙特卡洛模拟方案CFR和CEI之间呈中等相关(r=0.633),相关性无显著线性关系(P=0.367)。Objective According to the theory of pharmacokinetics/pharmacodynamics (PK/PD),Monte Carlo simulation of imipenem/cilastatin on Escherichia coli in the bloodstream infection regimen,combined with imipenem/ cilastatin on the .clinical efficacy of bloodstream infections,and the correlation between them were studied.Methods Retrospective investigation of imipenem/cilastatin resistance monitoring report on bloodstream infections caused by E. coli in our hospital from July 2013to June 2016.Regimens of imipenem/cilastatin(0.5g q8h,0.5g q6h,1.0g q12h,1.0g q8h)were used to calculate the cumulative fraction of response (CFR)of 10,000"real patients"and clinical efficacy index (CEI).The correlation of CFR and CEI was analyzed using SPSS24.0software.Results The CFR of dosing regimen of imipenem/cilastatin of 0.5g q6h was larger than 85.30%.The CEI of dosing regimen was bigger than 80%. Conclusion There was a moderate correlation between cumulative response fraction (CFR)and clinical efficacy index (CEI)in the Monte Carlo simulation program (r=0.633),and there was not a significant linear correlation between them (P=0.367).

关 键 词：蒙特卡洛模拟 临床疗效 亚胺培南/西司他丁 血流感染 相关性分析 

分 类 号：R978.1[医药卫生—药品]